OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Dorff on the Importance of Somatic Testing in mCRPC

March 22nd 2021

Tanya Dorff, MD, discusses the importance of somatic testing in metastatic castration-resistant prostate cancer.

Dr. Hamilton on the Evaluation of Lucitanib/Nivolumab in Gynecologic Cancers

March 22nd 2021

Erika P. Hamilton, MD, discusses the phase 2 LIO-1 trial evaluation of lucitanib and nivolumab across different gynecologic cancer subtypes.

Dr. Herrera on Camidanlumab Tesirine in Relapsed/Refractory Hodgkin Lymphoma

March 19th 2021

Alex Herrera, MD, discusses the potential role of camidanlumab tesirine in patients with relapsed/refractory Hodgkin Lymphoma, which is currently being examined in a phase 2 clinical trial.

Dr. Gibney on the Potential for Fixed-Duration Immunotherapy in Melanoma

March 19th 2021

Geoffrey T. Gibney, MD, discusses the potential utility of fixed-duration immunotherapy in melanoma.

Dr. Trent on the Utility of ctDNA to Understand Primary Mutations in GIST

March 19th 2021

Jonathan C. Trent, MD, PhD, discusses the utility of circulating tumor DNA to understand primary driver mutations in gastrointestinal stromal tumor.

Dr. Kazmi on Tailoring Treatment to Various Subtypes of CRC

March 19th 2021

Syed Kazmi, MD, discusses the importance of tailoring treatment to different subtypes of colorectal cancer.

Dr. Hanna on Approaching Biomarker Testing in Lung Cancer

March 18th 2021

Nasser H. Hanna, MD, discusses his approach to biomarker testing in lung cancer.

Dr. George on Actionable Pathogenic Variants in Adults With Breast or Ovarian Cancers in the Caribbean

March 18th 2021

Sophia George, PhD, discusses actionable pathogenic variants in patients with breast cancer who live in the Caribbean.

Dr. Hurley on Breast Cancer Baseline Characteristics in the Caribbean Vs the United States

March 18th 2021

Judith E. Hurley, MD, discusses the baseline characteristics of patients with breast cancer in the Caribbean vs those in the United States.

Dr. Choueiri on the CheckMate-9ER Exploratory Analysis in Advanced RCC

March 18th 2021

Toni K. Choueiri, MD, discusses results from an exploratory analysis of the phase 3 CheckMate-9ER trial in patients with advanced renal cell carcinoma.

Dr. Levy on the Importance of Testing for KRAS Mutations in Lung Cancer

March 18th 2021

Benjamin P. Levy, MD, discusses the importance of testing for KRAS mutations in lung cancer.

Dr. Martin on Determining Transplant Eligibility in Multiple Myeloma

March 18th 2021

Thomas G. Martin, MD, discusses factors that can inform transplant eligibility in multiple myeloma.

Dr. Salem on the FDA Approval of Y-90 Glass Microspheres for HCC

March 18th 2021

Riad Salem, MD, discusses the FDA approval of TheraSphere™ Yttrium-90 Glass Microsphere in March 2021 for the treatment of patients with hepatocellular carcinoma.

Dr. Spira on the Role of Broad Molecular Testing in Lung Cancer

March 17th 2021

Alexander Spira, MD, PhD, FACP, discusses the role of broad molecular testing in lung cancer.

Dr. Till on the Durability of Response With Brexucabtagene Autoleucel in MCL

March 16th 2021

Brian Till, MD, discusses the potential durability of brexucabtagene autoleucel in mantle cell lymphoma.

Dr. Atkins on the FDA Approval of Tivozanib in Relapsed/Refractory Advanced RCC

March 16th 2021

Michael B. Atkins, MD, discusses the FDA approval of tivozanib in relapsed/refractory advanced renal cell carcinoma.

Dr. Martin on the Utility of Aggressive Frontline Treatment in Multiple Myeloma

March 15th 2021

Thomas G. Martin, MD, discusses the utility of aggressive frontline treatment in multiple myeloma.

Dr. Goy on Next Steps With CAR T-Cell Therapy in MCL

March 12th 2021

Andre Goy, MD, discusses the next steps with CAR T-cell therapy in mantle cell lymphoma.

Dr. Kumar on the Challenges of Selecting Therapy in Heavily Pretreated Multiple Myeloma

March 12th 2021

Shaji K. Kumar, MD, discusses the challenges of selecting therapy for patients with heavily pretreated multiple myeloma.

Dr. Mead on the Role of BTK Inhibition After Venetoclax in Relapsed/Refractory CLL

March 12th 2021

Monica D. Mead, MD, discusses the role of BTK inhibition after venetoclax in relapsed/refractory chronic lymphocytic leukemia.